Please login to the form below

Not currently logged in

Voyager Therapeutics

This page shows the latest Voyager Therapeutics news and features for those working in and with pharma, biotech and healthcare.

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset

Mitokinin. "We look forward to executing on the collaborative research plan, and most of all, to developing much needed therapeutics for Parkinson's disease patients,” he added. ... in  August 2020, AbbVie ended a partnership with Voyager Therapeutics,

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...